Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus ipilimumab fixed-ratio combination versus sequential administration in previously untreated unresectable or metastatic melanoma
2016-001941-26Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of nivolumab, ipilimumab and BMS-986214 in melanoma (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Incidence of adverse events in anaphylactic reaction SMQ (broad scope). Started Sep 2016; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2016-001941-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001941-26.